SG11202103806VA - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament - Google Patents

4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Info

Publication number
SG11202103806VA
SG11202103806VA SG11202103806VA SG11202103806VA SG11202103806VA SG 11202103806V A SG11202103806V A SG 11202103806VA SG 11202103806V A SG11202103806V A SG 11202103806VA SG 11202103806V A SG11202103806V A SG 11202103806VA SG 11202103806V A SG11202103806V A SG 11202103806VA
Authority
SG
Singapore
Prior art keywords
pyrazin
ylmethyl
medicament
morpholine derivatives
morpholine
Prior art date
Application number
SG11202103806VA
Inventor
Riccardo Giovannini
Angelo Ceci
Cornelia Dorner-Ciossek
Roland Pfau
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11202103806VA publication Critical patent/SG11202103806VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103806VA 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament SG11202103806VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (en) 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
SG11202103806VA true SG11202103806VA (en) 2021-05-28

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103806VA SG11202103806VA (en) 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Country Status (36)

Country Link
US (2) US11166958B2 (en)
EP (1) EP3867244B1 (en)
JP (1) JP7093468B2 (en)
KR (1) KR20210079325A (en)
CN (1) CN112888685B (en)
AR (1) AR116711A1 (en)
AU (1) AU2019362330B2 (en)
BR (1) BR112021004993A2 (en)
CA (1) CA3113308A1 (en)
CL (1) CL2021000858A1 (en)
CO (1) CO2021004612A2 (en)
CR (1) CR20210184A (en)
DK (1) DK3867244T3 (en)
DO (1) DOP2021000069A (en)
EA (1) EA202191014A1 (en)
EC (1) ECSP21027009A (en)
ES (1) ES2940184T3 (en)
FI (1) FI3867244T3 (en)
HR (1) HRP20230249T1 (en)
HU (1) HUE061891T2 (en)
IL (1) IL282142B2 (en)
JO (1) JOP20210075A1 (en)
LT (1) LT3867244T (en)
MA (1) MA53898B1 (en)
MX (1) MX2021004418A (en)
PE (1) PE20211278A1 (en)
PH (1) PH12021550834A1 (en)
PL (1) PL3867244T3 (en)
PT (1) PT3867244T (en)
RS (1) RS63988B1 (en)
SA (1) SA521421756B1 (en)
SG (1) SG11202103806VA (en)
SI (1) SI3867244T1 (en)
TW (1) TWI828779B (en)
UA (1) UA128408C2 (en)
WO (1) WO2020079039A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376258B2 (en) * 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
MXPA04000737A (en) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Piperidine derivatives as nmda receptor antagonists.
AU2006322067A1 (en) * 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
SG11201501392TA (en) 2012-10-18 2015-05-28 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
EP3362447B1 (en) * 2015-10-14 2020-08-26 Bristol-Myers Squibb Company Selective nr2b antagonists

Also Published As

Publication number Publication date
CN112888685B (en) 2023-09-22
EP3867244B1 (en) 2023-01-18
SA521421756B1 (en) 2023-02-12
UA128408C2 (en) 2024-07-03
WO2020079039A1 (en) 2020-04-23
PH12021550834A1 (en) 2021-10-04
MA53898A (en) 2022-01-26
KR20210079325A (en) 2021-06-29
HRP20230249T1 (en) 2023-04-14
MA53898B1 (en) 2023-03-31
PL3867244T3 (en) 2023-05-22
PE20211278A1 (en) 2021-07-19
CO2021004612A2 (en) 2021-04-30
JOP20210075A1 (en) 2023-01-30
CL2021000858A1 (en) 2021-10-01
EA202191014A1 (en) 2021-11-09
JP7093468B2 (en) 2022-06-29
AR116711A1 (en) 2021-06-02
JP2022505080A (en) 2022-01-14
US20200121691A1 (en) 2020-04-23
IL282142A (en) 2021-05-31
AU2019362330B2 (en) 2024-03-28
RS63988B1 (en) 2023-03-31
EP3867244A1 (en) 2021-08-25
LT3867244T (en) 2023-03-10
SI3867244T1 (en) 2023-04-28
US20210393644A1 (en) 2021-12-23
CA3113308A1 (en) 2020-04-23
TWI828779B (en) 2024-01-11
US11166958B2 (en) 2021-11-09
IL282142B1 (en) 2023-12-01
ECSP21027009A (en) 2021-05-31
CN112888685A (en) 2021-06-01
HUE061891T2 (en) 2023-09-28
DK3867244T3 (en) 2023-05-01
BR112021004993A2 (en) 2021-06-08
FI3867244T3 (en) 2023-03-20
ES2940184T3 (en) 2023-05-04
TW202031262A (en) 2020-09-01
MX2021004418A (en) 2021-07-06
PT3867244T (en) 2023-02-22
AU2019362330A1 (en) 2021-04-08
IL282142B2 (en) 2024-04-01
CR20210184A (en) 2021-05-26
DOP2021000069A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
IL276952A (en) 2,4-diaminoquinazoline derivatives and medical uses thereof
IL257173A (en) Novel insulin derivatives and the medical uses hereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL276323A (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
GB2552063B (en) Medical scope accessory, medical scopes comprising the accessory, and use thereof
PT3796975T (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
IL282527A (en) Azaindazole-5 derivatives and their use
EP3715344A4 (en) 1,4-benzodiazapin-2-one derivatives and use thereof
IL282526A (en) Azaindazole-5 derivatives and their use
IL274868A (en) Imidazopyridine derivatives and the use thereof as medicament
IL282142A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
GB201813312D0 (en) Compounds and their therapeutic use
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
EP3703805A4 (en) Magnetically-assisted delivery into and through the skin
EP3718543A4 (en) Pharmaceutical composition and use thereof
GB201902087D0 (en) Medicament and the use thereof
GB201802743D0 (en) Medicament and use thereof
IL292646A (en) Pharmaceutical combination and use thereof
IL282157A (en) Compounds and therapeutic uses thereof
HK1254527A1 (en) Pharmaceutical formulation and use thereof
AU2016901401A0 (en) Webfish and the term "webfishing"